Shots:

• The P-III KEYNOTE-240 Study involves assessing of Keytruda (200mg- q3w) vs PBO in 413 patients with 1L advance HCC
• The study resulted in unmet 1EPs & 2EPs as OS- PFS & ORR- DOR- disease control rate and time to progression respectively in the trial
• Keytruda (pembrolizumab) 100mg IV is a mAb- used as an anti-D-L1 therapy that blocks the interaction between PD-1 and its ligands i.e PD-L1 & PD- L2- further activating T lymphocytes

Ref: Merck| Image: Merck